Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study

British Medical Journal

Volumn 321, Issue 7258, 2000, Pages 412-419

  Adler, Amanda I ^a   Stratton, Irene M ^a   Neil, H Andrew W ^b   Yudkin, John S ^c   Matthews, David R ^a   Cull, Carole A ^a   Wright, Alex D ^d   Turner, Robert C ^a   Holman, Rury R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d SELLY OAK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CATARACT; CATARACT EXTRACTION; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; SYSTOLIC BLOOD PRESSURE; TIME; VASCULAR DISEASE;

EID: 0034641550     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.321.7258.412     Document Type: Article

References (56)

1. 1 UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998;317:703-13.
2. 2 Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Epidemiological association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000; 321:405-12.
3. 3 Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-68.
4. 4 Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler, Hormann A, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich general practitioner project. Diabetologia 1996;39:1540-5.
5. 5 Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 1996;39:1577-83.
6. 6 Lehto S, Ronnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997;46:1354-9.
7. 7 Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycaemia on all-cause and cardiovascular mortality. Diabetes Care 1998;21:1167-72.
8. 8 Kannel W, McGee D. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8.
9. 9 Cowie CC, Harris MI. Physical and metabolic characteristics of persons with diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America. 2nd ed. Washington, DC: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995.
10. 10 Manson JAE, Colditz GA, Stampfer MJ. Willett WC, Krolewski AS, Rosner B, et al. A prospective study of maturity-onset diabetes mellitus and risk of corronary heart disease and stroke in women. Arch Intern Med 1991;151:1141-7.
11. 11 Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA 1991;265:627-31.
12. 12 Hypertension in Diabetes Study Group. HDS I: prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardio-vascular and diabetic complications. J Hypertens 1993;11:309-17.
13. 13 Keil JE, Sutherland SE, Knapp RG, Lackland DT, Gazes PG.Tyroler HA. Mortality rates and risk factors for coronary disease in black as compared with white men and women. N Engl J Med 1993;329:73-8.
14. 14 Collins R, Peto R, MacMahon S, Herbert P, Fiebach N, Eberlein K, et al. Blood pressure, stroke, and coronary heart disease. Lancet 1990;335:827-38.
15. 15 Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434-44.
16. 16 Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-7.
17. 17 Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993;36:1175-84.
18. 18 UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
19. 19 UKPDS Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia 1991;34:877-90.
20. 20 Hypertension in Diabetes Study Group. HDS III: prospective study of therapy in type 2 diabetic patients - efficacy of ACE inhibitor and β blocker. Diabetic Med 1994;11:773-82.
21. 21 UKPDS Group. UK prospective diabetes study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabetic Med 1994;11:534-44.
22. 22 Easton DF, Peto J, Babiker AG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med 1991;10:1025-35.
23. 23 SAS. Version 6. Cary, NC: SAS Institute, 1990.
24. 24 Heart Outcome Prevention Evaluation Study Investigators. Effect of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. N Engl J Med 2000;342:145-60.
25. 25 Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
26. 26 Borghi C, Ambrosioni E. Evidence-based medicine and ACE inhibition. J Cardiovasc Pharmacol 1998;32(suppl 2):24-35.
27. 27 Ferrari R. Effect of ACE inhibition on myocardial ischaemia. Eur Heart J 1998;19(suppl J):30-5.
28. 28 Doughty RN, Rodgers A, Sharpe N. MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure: a systematic overview of randomised controlled trails. Eur Heart J 1997; 18:560-5.
29. 29 Freemantle N, Cleland J, Young P, Mason J, Harrison J. β Blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ 1999;318:1730-7.
30. 30 Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-lines agents. JAMA 1997;277:739-45.
31. 31 UKPDS Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998;317:713:20.
32. 32 MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
33. 33 Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Sixth report. Arch Intern Med 1997;157:2413-46.
34. 34 Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Can Med Assoc J 1998;159(suppl 8):1-29.
35. 35 American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1998;21(suppl 1):23-31.
36. 36 British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):1-29.
37. 37 Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
38. 38 Vatlen LJ, Holmen J, Kruger O, Forsen L, Tverdal A. Low blood pressure and mortality in the elderly: a 6-year follow-up of 18,022 Norwegian men and women age 65 years and older. Epidemiology 1995;6:70-3.
39. 39 Goodkin G. Mortality in diabetes. A 20 year mortality study. J Occup Med 1975;17:716-21.
40. 40 Van den Hoogen PCW, Feskens EJM. Nagelkerke NJD, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med 2000;342:1-8.
41. 41 Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease among middle aged diabetic men: a general population study. BMJ 1989;299:1127-31.
42. 12 Bruno G, Merletti F, Boffetta P, Cavallo-Perin P, Bargero G, Gallone G, et al. Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortalily an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus. Diabetologia 1999;12:297-301.
43. 43 Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Preditors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996;27:63-8.
44. 44 Barrett-Connor E, Khaw K-T. Diabetes mellitus: an independent risk factor for stroke? Am J Epidemiol 1988;128:116-23.
45. 43 Palumbo PJ, Elveback I.R. Whisnant JP. Neurological complications of diabetes mellitus: transient ischemic attack, stroke, and peripheral neuropathy. Adv Neurol 1978;19:593-601.
46. 46 Tate RB, Manfreda J, Krahn AD, Cuddy TE. Tracking of blood pressure over a 40-year period in the University of Manitoba follow-up study, 1948-1988 Am J Epidemiol 1995;142:946-54.
47. 47 Cutler JA. High blood pressure and end-organ damage. J Hyperteus Suppl 1996;14:3-6.
48. 48 Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, et al. Effect of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;320:677-84.
49. 49 Curb JD, Pressel SL, Cutler JA, Savage P, Applegate WB, Black H, et al. Effect of diuretíc-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic hypertension in the elderly program cooperative research group. JAMA 1996;276:1886-92.
50. 50 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
51. 51 Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care 1996;19:1051-61.
52. 52 UKPDS Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes (UKPDS 40). BMJ 1998;317:720-6.
53. 53 UKPDS Group. UK prospective diabetes study 16: overview of six years' therapy of type 2 diabetes - a progressive disease. Diabetes 1995;44:1249-58.
54. 54 Svetkey LP. Simons-Morton D, Vollmer WM, Appel LJ. Conlin PR, Ryan DH, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the dietary approaches to stop hypertension (DASH) randomized clinical trial. Arch Intern Med 1999;159:283-93.
55. 55 Eriksson J, Lindström J, Valle T, Annola S, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the diabetes prevention study in Finland. Diabetologia 1999;42:793-801.
56. 56 Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ 1981;282:1847-51.